Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity

What Was Tested

The paper reports a study of Exenatide in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.

Their goal was to investigate appetite/satiety hormones and eating behaviours that may predict WLM with exenatide (a GLP1-RA) versus placebo in adolescents with severe obesity.

Who Took Part

PubMed indexes the participants as teenagers, both men and women.

In this secondary analysis, eating behaviours and appetite/satiety regulation hormones post-meal replacement therapy (pre-randomization to exenatide or placebo) were evaluated as possible predictors of WLM.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

Percent change in BMI from randomization to 52 weeks served as the primary measure of WLM.

What Was Measured

The subject headings attached to it are Obesity, Morbid, Exenatide, Leptin, Appetite, Pediatric Obesity, Weight Loss and Feeding Behavior.

The authors tagged it with the keywords glucagon‐like peptide‐1 receptor agonist and weight regain.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exenatide in people with fat loss, obesity & body recomposition.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Pediatric obesity), a journal based in England.

More context: the Exenatide compound page, Fat loss, obesity & body recomposition research.